Safety and efficacy of tenofovir in chronic hepatitis B-related decompensated cirrhosis

Table 1 Baseline characteristics of the compensated and decompensated liver cirrhosis groups

	All (n = 174)	Compensated LC (n = 117)	Decompensated LC (n = 57)	P value
Male/female	114/60	73/44	41/16	0.238
Age (yr)	52.2 ± 11.0	52.3 ± 11.0	51.9 ± 11.0	0.889
HBeAg positive	78/96 (44.8%)	50/67 (42.7%)	28/29 (49.1%)	0.516
HBV DNA (log10 copies/mL)	6.49 ± 1.40	6.34 ± 1.40	6.79 ± 1.35	0.065
ALT (IU/L)	92.8 ± 165.6	77.2 ± 115.2	124.4 ± 235.5	0.014
TB (mg/dL)	1.71 ± 2.40	1.06 ± 0.97	3.04 ± 3.61	0.000
PT INR	1.27 ± 0.29	1.14 ± 0.12	1.49 ± 0.36	0.000
Albumin (g/dL)	3.9 ± 2.95	4.35 ± 3.51	3.03 ± 0.66	0.000
Platelet count(103/μL)	115.0 ± 48.5	127.7 ± 47.4	90.9 ± 41.1	0.000
Child score	6.1 ± 1.6	5.2 ± 0.5	8.0 ± 1.5	0.000
MELD score	10.1 ± 4.0	8.3 ± 1.87	13.4 ± 4.76	0.000
Ascites			20
Episode of HE			1
Episode of varix bleeding			4

LC: Liver cirrhosis.